Gland Pharma Limited (NSE: GLAND, BSE: 543245) is a Hyderabad, Telangana-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹50,206 Cr, it ranks #196 by market cap among the 6,137 Indian listed companies on FinBizNet, and #11 of 86 in Medicinal Chemicals and Botanical Products. At ₹2,826.80 (as of 25 Oct 2026), the share price is 10.9% below its 52-week high of ₹3,171.00 and 79.6% above its 52-week low of ₹1,573.60. The share price is up 46.0% over one year and up 18.8% over three months.
| Current Price | ₹2,826.80 |
|---|---|
| Market Cap | ₹50,206 Cr |
| NSE Symbol | GLAND |
| BSE Code | 543245 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 48.4 |
| Return on Equity | 10.53% |
| Return on Assets | 6.27% |
| 52-Week Range | ₹1,573.60 – ₹3,171.00 |
| 1-Year Price Change | +46.0% |
| 3-Month Price Change | +18.8% |
| Beta (1Y) | 0.45 |
| Dividend Yield | 0.66% |
| Headquarters | Hyderabad, Telangana |
| Website | www.glandpharma.com |
| Revenue | ₹1,800 Cr |
|---|---|
| Net Profit | ₹317 Cr |
| Net Margin | 17.6% |
| EPS (Basic) | ₹19.23 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Gland Pharma Limited engages in manufacturing and sale of injectable formulations in India, the United States, Europe, Canada, Australia, New Zealand, and internationally. It engages in research and development of pharmaceutical active pharmaceutical ingredient products, including synthesis of complex drug molecules, such as low molecular weight heparins, corticosteroids, peptides, and cytotoxic molecules. The company also offers its products for various therapeutic categories, such as anti- diabetic, anti-malarial, anti-infectives, anti-neoplastic, blood related, cardiac, gastro-intestinal, gynaecological, hormones, neuro/Cns, ophthal/otological, and other areas, as well as pain/analgesics, respiratory and pulmonology, and vitamins, minerals, and nutrients. In addition, it provides contract development, dossier compilation, technology transfer services. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited operates as a subsidiary of Fosun Pharma
1. Pharmaceuticals-This segment manufactures generic injectables.
1. Pharmaceuticals-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4,21,995 Cr | 36.4 | 14.72% | ₹15,300 Cr | +5.4% |
| Zydus Lifesciences Ltd | ₹1,12,020 Cr | 22.2 | 18.32% | ₹8,017 Cr | +14.7% |
| Laurus Labs Ltd | ₹1,11,310 Cr | 125.3 | 17.74% | ₹2,026 Cr | +125.7% |
| Cipla Limited | ₹1,07,048 Cr | 27.6 | 11.74% | ₹7,119 Cr | -14.7% |
| Dr.Reddys Lab | ₹1,02,611 Cr | 24.1 | 11.52% | ₹8,698 Cr | -0.9% |
| Aurobindo Pharma Ltd. | ₹95,910 Cr | 26.8 | 9.93% | ₹9,150 Cr | +41.7% |
| Mankind Pharma | ₹93,977 Cr | 48.7 | 12.45% | ₹4,031 Cr | -9.9% |
| Lupin Ltd | ₹89,426 Cr | 16.6 | 26.91% | ₹8,277 Cr | -1.1% |
| Gland Pharma Limited | ₹50,206 Cr | 48.4 | 10.53% | ₹1,800 Cr | +46.0% |
Listed by market capitalisation. Ratios are shown for context only.
Gland Pharma Limited is trading at ₹2,826.80, with a market capitalisation of ₹50,206 Cr.
Gland Pharma Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).
Gland Pharma Limited has a P/E of 48.4 and a return on equity of 10.53%.
Gland Pharma Limited is listed on the NSE under the symbol GLAND and on the BSE under the scrip code 543245.
Gland Pharma Limited's share price is up 46.0% over one year and up 18.8% over three months. Its 52-week range is ₹1,573.60 to ₹3,171.00.
In Q1 FY27, Gland Pharma Limited reported revenue of ₹1,800 Cr and net profit of ₹317 Cr, with basic EPS of ₹19.23 (consolidated, parsed from the company's exchange filing).
Data as of 25 Oct 2026. Descriptive market data only — not investment advice.